thymosin alpha-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
== Clinical significance == MT-TD mutations have been associated with complex IV deficiency of the mitochondrial respiratory chain, also known as cytochrome c oxidase deficiency. Cytochrome c oxidase deficiency is a rare genetic condition that can affect multiple body parts, including skeletal muscles, the heart, the brain, or the liver. Common clinical manifestations include myopathy, hypotonia, and encephalomyopathy, lactic acidosis, and hypertrophic cardiomyopathy. A patient with a 7526A>G mutation in the MT-TD gene exhibited gradually worsening symptoms of exercise intolerance, increased creatine kinase levels, sustained exercise leading to muscle pains and general malaise. A patient with a 7543A>G mutation also exhibited symptoms of the disease.
1993/169) Combined Probation Areas (Kent) Order 1993 (S.I. 1993/173) Insurance Companies (Amendment) Regulations 1993 (S.I. 1993/174) Council Tax (Transitional Reduction Scheme) (England) Regulations 1993 (S.I. 1993/175) Motor Vehicles (Wearing of Seat Belts) Regulations 1993 (S.I. 1993/176) Loch Crinan Scallops Fishery Order 1993 (S.I. 1993/177) Local Government Act 1988 (Defined Activities) (Specified Periods) (Scotland) Amendment Regulations 1993 (S.I. 1993/178) Air Navigation (Dangerous Goods) (Fourth Amendment) Regulations 1992 S.I. 1993/179) City of London (Non-Domestic Rating Multiplier) Order 1993 (S.I. 1993/180) Sea Fish Licensing (Variation) Order 1993 (S.I. 1993/188) Spring Traps Approval (Variation) Order 1993 (S.I. 1993/189) New Severn Bridge (Restriction of Navigation) Regulations 1993 (S.I. 1993/190) Council Tax and Non-Domestic Rating (Demand Notices) (England) Regulations 1993 (S.I. 1993/191) Value Added Tax Act 1983 (Interest on Overpayments etc.) (Prescribed Rate) Order 1993 (S.I. 1993/192) Copyright (Certification of Licensing Scheme for Educational Recording of Broadcasts and Cable Programmes) (Educational Recording Agency Limited) (Amendment) Order 1993 (S.I. 1993/193) Local Government Finance Act 1992 (Commencement No. 7 and Amendment) Order 1993 (S.I. 1993/194) Council Tax (Reductions for Disabilities) (Amendment) Regulations 1993 (S.I. 1993/195) Council Tax (Administration and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/196) Friendly Societies Act 1992 (Commencement No. 4) Order 1993 (S.I.
== Human sexual orientation and behavior genetics == In the 1990s Hamer began studies on the genetics of human behavior, which led to the first molecular evidence for genes that influence human sexual orientation. His research group's first paper, published in Science in 1993, reported that the maternal but not paternal male relatives of gay men had increased rates of same-sex orientation, suggesting the possibility of sex-linked transmission in a portion of the population. A genetic linkage analysis of DNA samples from these families showed that gay brothers had an increased probability of sharing polymorphic markers on the subtelomeric region of the long arm of the X chromosome, Xq28, providing statistically significant evidence for linkage to the sexual orientation phenotype. This finding was replicated in two other studies in the United States whereas a study in Canada found contrary results; meta-analysis of all data available at that time suggested that Xq28 has a significant but not exclusive effect. Subsequently, a genomewide scan by Hamerʻs group revealed additional regions on autosomes that were moderately linked to male sexual orientation. Hamer's results were supported in 2014 in a large, multi-center genetic linkage study of male sexual orientation. This study's analysis of 409 pairs of gay brothers with over 300,000 single-nucleotide polymorphism markers confirmed the Xq28 linkage by two-point and multipoint LOD score mapping.
Spriggina fossils represent the first known organisms with a bilaterally symmetric body plan. They had a head, tail and almost identical halves. They probably had sensory organs in the head and digestive organs in the tail which would have allowed them to find food more efficiently. They were capable of locomotion, which gave them an advantage over other organisms from that era that were either tethered to the bottom of the ocean floor or moved very slowly. Spriggina was soft bodied, which leave the fossils as faint imprints. It is most likely related to annelids, however there is some speculation that it could be related to arthropods since it somewhat resembles trilobite fossils.
Sources: en.wikipedia.org
The Cape cobra (Naja nivea) is regarded as one of the most dangerous species of cobra in Africa, by virtue of its potent venom and frequent occurrence around houses. The venom of this snake tends to be thick and syrupy in consistency and dries into shiny pale flakes, not unlike yellow sugar. The Cape cobras venom is made up of potent postsynaptic neurotoxins and might also contain cardiotoxins, that affect the respiratory system, nervous system, and the heart. The mouse SC LD50 for this species' venom is 0.72, while the IV and IP LD50 values are 0.4 mg/kg and 0.6 mg/kg, respectively. The average venom yield per bite is 100 to 150 mg according to Minton. The mortality rate for untreated bites is not exactly known, but is thought to be high. This can be because of various factors including the amount of venom injected, psychological state of the bitten subject and the penetration of one or both fangs. Mechanical ventilation and symptom management is often enough to save a victim's life, but cases of serious Cape cobra envenomation will require antivenom. When death does occur, it normally takes anywhere from an hour (in severe cases) to ten hours (or more) and it is often as a result of respiratory failure, because of the onset of paralysis. The antivenom used in case of a bite is a polyvalent antivenom produced by the South African Institute of Medical Research (SAIMR).
Jenny Pearce is the Professor of Young People and Public Policy at the University of Bedfordshire. Her research interests include the investigation of child sexual exploitation. She was a member of the original panel of the Independent Panel Inquiry into Child Sexual Abuse prior to the inquiry's reconstitution in January 2015. She is an Officer of the Order of the British Empire. Bedfordshire University has been awarded the Queen's Anniversary Prize for applied research on child sexual exploitation influencing new safeguarding policy and practice that she has led in her role as director of The International Centre, researching child sexual exploitation, violence and trafficking.
== Structure == The active bifunctional enzyme of trypanothione synthase is found as a 74.4 KDa monomer consisting of 652 residues with two catalytic domains. Its C-terminal domain is a synthetase and has an ATP-grasp family fold that is usually found in carbon-nitrogen ligases. The N-terminal domain is a cysteine, histidine-dependent aminohydrolase amidase. Structurally the synthetase and amidase domains are bound together by three residues of Glu-650-Asp-651-Glu-652 through hydrogen bonding and salt bridge interactions with basic side chains in order for the protein to properly fold. These three residues also block the catalytic Cys-59 in the amidase domain. It is currently known that the synthetase active site is shaped in the fashion of a triangular cavity that binds the three substrates such that the end of each molecule is nestled in a vertex of the triangle. The particular residues of Arg-553 and Arg-613 have been found to key for synthetic function, however further research into the structure of trypanothione synthase must be done in order to fully understand the enzyme's active sites.
Acrogeria Berardinelli-Seip congenital lipodystrophy (congenital generalized lipodystrophy) Cockayne syndrome Ehlers–Danlos syndromes, progeroid form Gerodermia osteodysplastica Hallermann–Streiff syndrome Mandibuloacral dysplasia Neonatal progeroid syndrome (Wiedemann–Rautenstrauch syndrome) Nestor-Guillermo syndrome Penttinen syndrome Petty–Laxova–Weidemann progeroid syndrome POLR3A-related Wiedemann–Rautenstrauch syndrome PYCR1-related Wiedemann–Rautenstrauch-like syndrome Werner syndrome
== Sizes == While small-scale columns range from inner diameters of 0.5 cm and withstand pressures of up to 130 MPa, industrial large scale columns reach diameters of up to 2 m and operate at considerable lower pressures (below 1 MPa). While it is favorable to view the packed bed of a column large scale columns are manufactured from steel due to its superior resilience. Chromatography columns can be used as stand-alone devices or in combination with manual or automated chromatography systems. Medium to large columns are almost exclusively operated together with automated systems to decrease the risk of process failure and loss of product.
Sources: en.wikipedia.org
== Future potential applications == In the future, radioligand therapy may expand to include more α-emitter based treatments. Currently, β radioligand therapies are more commonly used in oncology. Clinical trials of α-emitters are underway due to their higher potency and ability to induce double-strand DNA breaks. There are multiple Actinium-225 based PSMA studies that will be launched in 2024. If these prove successful, there is potential for further studies and clinical trials to be done using α-emitters. There is potential for the future use of radioligand therapy in patients with malignant brain tumors. There have been recent developments in diagnostic tracers using radioligands, and with radioligand-based imaging techniques and in the field of theranostics.
== Legacy == In 1994, Banting was inducted into the Canadian Medical Hall of Fame. In 2004, he was nominated as one of the top 10 "Greatest Canadians" by viewers of the Canadian Broadcasting Corporation. When the final votes were counted, Banting finished fourth behind Tommy Douglas, Terry Fox and Pierre Trudeau.
== DHEA in regards to aging == DHEA levels peak in early adulthood and gradually decline with age. By supplementing with DHEA, some individuals aim to restore hormone levels, potentially improving energy levels, mood, and libido. DHEA can help improve bone density as it is related to androgens which is important for bone health. DHEA controls the production of osteoblasts and insulin like growth factor 1 (IGF-1) expression which strengthens bone growth through metabolites. This helps delay the risk of osteoporosis in early adults.
=== Biphasic half-life === Many drugs show a biphasic decline in plasma concentration after a dose: a steep distribution phase as drug leaves the central compartment for tissues (α phase), followed by a shallower elimination phase as drug is cleared (β phase). On a semi-log plot the two phases are approximately linear, with slopes α and β, and corresponding half-lives t1/2α = 0.693/α and t1/2β = 0.693/β. For single doses of lipophilic, multi-compartment drugs, clinical duration after onset is often driven by the distribution (α) phase, because by the time distribution equilibrium is reached plasma levels are frequently below any minimal effective concentration, so the terminal β phase has little bearing on observable effects. As a result, classifying drugs by terminal (β) half-life can poorly predict duration of action, whereas α half-life is often more informative—though less commonly reported in labels and reviews. Exceptions exist when elimination is extremely rapid: for very short-acting agents, the β phase can meaningfully shorten effect duration even after a single dose (e.g., triazolam, midazolam). The longer half-life is called the terminal half-life and the half-life of the largest component is called the dominant half-life. For a more detailed description see Pharmacokinetics § Multi-compartmental models.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.